Storia in 18 fonti

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.

Raccontata da

www1.folha.uol.com.br

morningstar.com+6 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo12 h fa

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers

AstraZeneca and Bristol Myers explore $400B pharma merger; BMY shareholders gain ~1/3 in all-stock transaction. Eliquis patent expiration (April 2028) plus $50B combined revenue loss by 2030 require synergies despite UK regulatory challenges.

originale

Timeline cronologica

domenica 2 agosto 2026·www1.folha.uol.com.br
AstraZeneca negocia fusão com Bristol Myers Squibb em acordo de US$ 400 bi
Acordo pode criar a quarta maior farmacêutica do mundo por capitalização de mercado
domenica 2 agosto 2026·handelsblatt.com
Pharma: AstraZeneca erwägt Mega-Fusion mit US-Rivalen Bristol Myers Squibb
Es wäre eine der größten Fusionen in der Wirtschaftsgeschichte. Laut einem Medienbericht wurden entsprechende Gespräche geführt. Ob es zu einem Zusammenschluss kommt ist jedoch…

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers

Confronto fonti

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers

Timeline cronologica

AstraZeneca negocia fusão com Bristol Myers Squibb em acordo de US$ 400 bi

Pharma: AstraZeneca erwägt Mega-Fusion mit US-Rivalen Bristol Myers Squibb

AstraZeneca, BMS discuss $400B pharma mega-deal

AstraZeneca, Bristol Myers are in talks about merger — report

$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"

Pharma giants AstraZeneca and Bristol-Myers in reported merger talks

AstraZeneca Stock Nosedives On Mega-Merger Rumor

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Pharma giants AstraZeneca, Bristol Myers Squibb in talks on $512 billion megadeal: Report

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)

AstraZeneca, Bristol Myers are in talks about merger — report

AstraZeneca said to have explored Bristol Myers merger | Fortune

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Ft, AstraZeneca tratta con Bristol Myers Squibb maxi fusione da 400 miliardi

Ft: AstraZeneca tratta con Bristol Myers Squibb fusione da 400 mld

Pharma: Astra-Zeneca erwägt wohl Mega-Fusion mit Bristol-Myers Squibb

AstraZeneca: Pharmakonzern prüft 400-Milliarden-Dollar-Fusion mit Bristol Myers

AstraZeneca Held Talks to Combine With Bristol Myers Squibb, FT Says, Citing Sources

Astrazeneca explores $400bn megadeal with US rival

AstraZeneca in talks over £300bn mega-merger with US rival – reports

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

Financial Times: 'AstraZeneca tratta con Bristol Myers Squibb per una maxi fusione da 400 miliardi' - Notizie - Ansa.it

AstraZeneca, BMS discuss $400B pharma mega-deal

AstraZeneca e Bristol Myers trattano la maxi fusione, può nascere un colosso farmaceutico da 400 miliardi | MilanoFinanza News

Las farmacéuticas AstraZeneca y Bristol Myers Squibb negocian una fusión de 348.000 millones de euros